Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imipenem + metronidazole is a combination of two antibiotics used together, primarily in the treatment of complicated intra-abdominal infections and other severe mixed aerobic-anaerobic bacterial infections. Imipenem is a carbapenem β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. Metronidazole is a nitroimidazole antibiotic with potent activity against anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis through reduction of its nitro group within susceptible organisms. The combination provides broad-spectrum coverage against both aerobic (including many Gram-negative) and anaerobic pathogens commonly encountered in intra-abdominal sepsis[1][2][9]. This regimen is often used when polymicrobial infection is suspected or confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on imipenem + metronidazole.